Developing advanced sensors to detect harmful molecules in cells
Structure-guided and high-throughput engineering of genetically encoded sensors for reactive oxygen species
This study is working on better sensors to measure harmful substances in the body that can lead to serious health problems like heart disease and brain disorders, helping doctors keep an eye on these issues in real-time for conditions like Alzheimer's and heart disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10774235 on NIH RePORTER |
What this research studies
This research focuses on creating improved sensors that can detect reactive oxygen species (ROS), which are linked to serious health issues like heart disease and neurodegeneration. By using innovative protein engineering and high-throughput screening techniques, the researchers aim to enhance the sensitivity and effectiveness of these sensors. This will allow for real-time monitoring of oxidative stress in various disease models, particularly in conditions affecting the brain and heart. The goal is to provide better tools for understanding and potentially treating diseases such as Alzheimer's and cardiovascular disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with neurodegenerative diseases like Alzheimer's or those suffering from cardiovascular disorders.
Not a fit: Patients with conditions unrelated to oxidative stress or those not experiencing neurodegeneration or cardiovascular issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better diagnostic tools and treatments for conditions related to oxidative stress, such as Alzheimer's disease and heart diseases.
How similar studies have performed: Previous research has shown promise in developing sensors for cellular monitoring, suggesting that this approach could yield significant advancements.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Berndt, Andre — University of Washington
- Study coordinator: Berndt, Andre
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.